Predictors of Benefit from Immune Checkpoint Inhibitors in Urothelial Carcinoma of the Bladder: The Limits of PD-L1 and the Rise of Circulating Tumor DNA-Guided Adjuvant Therapy.
Immune checkpoint inhibitors (ICIs) are established across the treatment continuum of urothelial carcinoma of the bladder, yet most patients derive no durable benefit. This narrative review appraises candidate predictors of ICI benefit in bladder urothelial carcinoma, distinguishing prognostic from predictive biomarker...